Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12616000540415
Ethics application status
Approved
Date submitted
2/02/2016
Date registered
27/04/2016
Date last updated
27/04/2016
Type of registration
Retrospectively registered
Titles & IDs
Public title
Safety of Manuka honey CycloPower ophthalmic cream
Query!
Scientific title
Effect of Manuka honey CycloPower ophthalmic micro-emulsion cream on ocular parameters in healthy participants compared with no treatment
Query!
Secondary ID [1]
288466
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Blepharitis
297499
0
Query!
Condition category
Condition code
Eye
297689
297689
0
0
Query!
Diseases / disorders of the eye
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Intervention involves external application of Manuka honey CycloPower ophthalmic cream (0.5-1ml) to the skin of the upper and lower eyelids of one eye only (randomised to the right or left eye), once daily for 2 weeks. The fellow (untreated) eye serves as the control. Compliance is monitored through follow-up telephone calls and the weighing of returned unused cream.
Query!
Intervention code [1]
293800
0
Treatment: Other
Query!
Comparator / control treatment
No treatment
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
297227
0
Skin hyperaemia as measured by VAS grading by the researcher
Query!
Assessment method [1]
297227
0
Query!
Timepoint [1]
297227
0
Day 7 and Day 14 after treatment commencement
Query!
Secondary outcome [1]
320408
0
Dry eye signs as measured by keratography
Query!
Assessment method [1]
320408
0
Query!
Timepoint [1]
320408
0
Day 7 and Day 14 after treatment commencement
Query!
Eligibility
Key inclusion criteria
1. Male or female healthy subjects aged 18-45 and in good health as determined by past medical history, physical examination, vital signs at screening.
2. Subjects must be able to communicate well with the investigator, to understand and comply with the requirements of the study and understand and sign the written informed consent.
3. Be willing not to wear contact lenses for 2 days prior to the start of the study and for the duration of the study
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
45
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
1. Known allergy to any components of the microemulsion (bee products or Manuka honey Cyclopower)
2. Pregnancy or planned pregnancy during the course of the study
3. A past medical history or evidence of significant dermatological conditions e.g. eczema, dermatitis
4. A past medical history or evidence of ophthalmic disease that could affect study outcomes
5. A past history or evidence of systemic disease that could affect the study outcomes
6. Dosing of a study drug in any clinical investigation within 30 days prior to initial treatment in this study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Treated eye and control eye allocation will be randomised and concealed from the investigator via opaque sealed envelopes given to the subjects.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A computer-generated randomisation schedule allocates the left/right eye to treatment/control
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people administering the treatment/s
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Paired eye study
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Safety
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
8/12/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
24/04/2015
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
25
Query!
Accrual to date
Query!
Final
25
Query!
Recruitment outside Australia
Country [1]
7567
0
New Zealand
Query!
State/province [1]
7567
0
Auckland
Query!
Funding & Sponsors
Funding source category [1]
292810
0
Commercial sector/Industry
Query!
Name [1]
292810
0
Manuka Health New Zealand Ltd
Query!
Address [1]
292810
0
34 Hannigan Dr, St Johns, Auckland 1072
Query!
Country [1]
292810
0
New Zealand
Query!
Primary sponsor type
University
Query!
Name
The University of Auckland
Query!
Address
85 Park Road, Grafton, Auckland, 1023
Query!
Country
New Zealand
Query!
Secondary sponsor category [1]
291549
0
Commercial sector/Industry
Query!
Name [1]
291549
0
Manuka Health New Zealand Ltd.
Query!
Address [1]
291549
0
34 Hannigan Dr, St Johns, Auckland 1072
Query!
Country [1]
291549
0
New Zealand
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
294311
0
University of Auckland Human Participants Ethics Committee
Query!
Ethics committee address [1]
294311
0
Private Bag 92019 Auckland 1142
Query!
Ethics committee country [1]
294311
0
New Zealand
Query!
Date submitted for ethics approval [1]
294311
0
08/09/2014
Query!
Approval date [1]
294311
0
03/12/2014
Query!
Ethics approval number [1]
294311
0
013084
Query!
Summary
Brief summary
Blepharitis, or inflammation of the eyelid, is a common, debilitating and chronic condition. This disease manifests clinically as either anterior blepharitis affecting the front portion of the eyelid and the eyelashes, or posterior blepharitis which involves the inner eyelid. Posterior blepharitis is usually caused by dysfunction of the lipid-producing meibomian glands in the eyelid and both types of blepharitis increase the susceptibility of the eyelids to over-colonisation by bacteria. Existing treatments for eyelid disease are costly and ineffective, and no readily and commercially available ophthalmic product targets both the bacterial and inflammatory disease processes. Both the anti-bacterial and anti-inflammatory effects of New Zealand native Manuka honey have been proven, and it has been shown in research conducted in collaboration with Medihoney Antibacterial Honey (Medihoney Pty Ltd., Australia) that a honey-based ophthalmic formation may have a therapeutic effect in blepharitis and meibomian gland dysfunction (MGD). Therefore, there is a clear rationale for developing a novel ophthalmic product based on New Zealand native Manuka honey for reducing the bacterial load, and the level of inflammation in blepharitis and MGD. We identified the species of bacteria present on the eyelids of people affected by eyelid disease and demonstrated that Manuka Honey with CycloPower has an anti-bacterial effect on these specific microorganisms. Subsequently, we developed a formulation of Manuka Honey with CycloPower suitable for use externally around the eye and the safety and lack of toxicity of this product was demonstrated first in a corneal epithelial cell line in vitro, and then in vivo in an animal study. Thus, we hypothesise that the use of Manuka Honey with CycloPower may be safe and well tolerated in healthy human volunteers in this present trial.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
63254
0
A/Prof Jennifer P Craig
Query!
Address
63254
0
Department of Ophthalmology
Faculty of Medical and Health Sciences
The University of Auckland
Private Bag 92019
Auckland 1142
Query!
Country
63254
0
New Zealand
Query!
Phone
63254
0
+6499238173
Query!
Fax
63254
0
+6493677173
Query!
Email
63254
0
[email protected]
Query!
Contact person for public queries
Name
63255
0
Jennifer P Craig
Query!
Address
63255
0
Department of Ophthalmology
Faculty of Medical and Health Sciences
The University of Auckland
85 Park Rd, Grafton
Auckland 1142
Query!
Country
63255
0
New Zealand
Query!
Phone
63255
0
+6499238173
Query!
Fax
63255
0
+6493677173
Query!
Email
63255
0
[email protected]
Query!
Contact person for scientific queries
Name
63256
0
Jennifer P Craig
Query!
Address
63256
0
Department of Ophthalmology
Faculty of Medical and Health Sciences
The University of Auckland
85 Park Rd, Grafton
Auckland 1142
Query!
Country
63256
0
New Zealand
Query!
Phone
63256
0
+6499238173
Query!
Fax
63256
0
+6493677173
Query!
Email
63256
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Dimensions AI
Randomised masked trial of the clinical safety and tolerability of MGO Manuka Honey eye cream for the management of blepharitis
2017
https://doi.org/10.1136/bmjophth-2016-000066
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF